Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H11N5O3 |
Molecular Weight | 225.2046 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC2=C(N=CN2COCCO)C(=O)N1
InChI
InChIKey=MKUXAQIIEYXACX-UHFFFAOYSA-N
InChI=1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)
Molecular Formula | C8H11N5O3 |
Molecular Weight | 225.2046 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018828s030,020089s019,019909s020lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020487s016lbl.pdfCurator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT01682109 | https://www.ncbi.nlm.nih.gov/pubmed/19957998 | https://www.ncbi.nlm.nih.gov/pubmed/7625798 | https://www.ncbi.nlm.nih.gov/pubmed/11454935
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018828s030,020089s019,019909s020lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020487s016lbl.pdf
Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT01682109 | https://www.ncbi.nlm.nih.gov/pubmed/19957998 | https://www.ncbi.nlm.nih.gov/pubmed/7625798 | https://www.ncbi.nlm.nih.gov/pubmed/11454935
Valacyclovir is the hydrochloride salt of the L-valyl ester of the antiviral drug acyclovir. Valacyclovir is a nucleoside analog DNA polymerase inhibitor. Valacyclovir hydrochloride is rapidly converted to acyclovir which has demonstrated antiviral activity against HSV types 1 (HSV-1) and 2 (HSV-2) and VZV both in cell culture and in vivo. The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts acyclovir into acyclovir monophosphate, a nucleotide analog. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. In biochemical assays, acyclovir triphosphate inhibits replication of herpes viral DNA. This is accomplished in 3 ways: 1) competitive inhibition of viral DNA polymerase, 2) incorporation and termination of the growing viral DNA chain, and 3) inactivation of the viral DNA polymerase. The greater antiviral activity of acyclovir against HSV compared with VZV is due to its more efficient phosphorylation by the viral TK. The resistance of HSV and VZV to acyclovir can result from qualitative and quantitative changes in the viral TK and/or DNA polymerase. Clinical isolates of VZV with reduced susceptibility to acyclovir have been recovered from patients with AIDS. Valaciclovir is indicated for the treatment of HSV and VZV infections, including Oral and genital herpes simplex (treatment and prophylaxis), Reduction of HSV transmission from people with recurrent infection to uninfected individuals, Prevention of cytomegalovirus following organ transplantation, Prophylaxis against herpesviruses in immunocompromised patients (such as patients undergoing cancer chemotherapy). Common adverse drug reactions (≥1% of patients) associated with valaciclovir therapy are the same as for aciclovir, its active metabolite, and include nausea, vomiting, diarrhea, and headache. Infrequent adverse effects (0.1–1% of patients) include agitation, vertigo, confusion, dizziness, edema, arthralgia, sore throat, constipation, abdominal pain, rash, weakness and/or renal impairment. Rare adverse effects (<0.1% of patients) include coma, seizures, neutropenia, leukopenia, tremor, ataxia, encephalopathy, psychotic symptoms, crystalluria, anorexia, fatigue, hepatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis and/or anaphylaxis.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12878501 | https://www.ncbi.nlm.nih.gov/pubmed/20038622https://www.ncbi.nlm.nih.gov/pubmed/12878501
Curator's Comment: Valacyclovir hydrochloride is rapidly converted to acyclovir which was detected in CSF after oral administration of valacyclovir.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1820 |
|||
Target ID: CHEMBL1872 |
0.08 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ZOVIRAX Approved UseOral ZOVIRAX® (acyclovir) is indicated for the treatment:
Herpes Zoster Infections: ZOVIRAX is indicated for the acute treatment of herpes zoster (shingles).
Genital Herpes: ZOVIRAX is indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes.
Chickenpox: ZOVIRAX is indicated for the treatment of chickenpox (varicella).
Injectable ZOVIRAX® (acyclovir) is indicated for the treatment:
Herpes Simplex Infections in Immunocompromised Patients: ZOVIRAX for Injection is
indicated for the treatment of initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) in immunocompromised patients.
Initial Episodes of Herpes Genitalis: ZOVIRAX for Injection is indicated for the treatment of severe initial clinical episodes of herpes genitalis in immunocompetent patients.
Herpes Simplex Encephalitis: ZOVIRAX for Injection is indicated for the treatment of herpessimplex encephalitis.
Neonatal Herpes Simplex Virus Infection: ZOVIRAX for Injection is indicated for the treatmentof neonatal herpes infections.
Varicella-Zoster Infections in Immunocompromised Patients: ZOVIRAX for Injection is
indicated for the treatment of varicella-zoster (shingles) infections in immunocompromised patients. Launch Date3.86208006E11 |
|||
Primary | ZOVIRAX Approved UseOral ZOVIRAX® (acyclovir) is indicated for the treatment:
Herpes Zoster Infections: ZOVIRAX is indicated for the acute treatment of herpes zoster (shingles).
Genital Herpes: ZOVIRAX is indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes.
Chickenpox: ZOVIRAX is indicated for the treatment of chickenpox (varicella).
Injectable ZOVIRAX® (acyclovir) is indicated for the treatment:
Herpes Simplex Infections in Immunocompromised Patients: ZOVIRAX for Injection is
indicated for the treatment of initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) in immunocompromised patients.
Initial Episodes of Herpes Genitalis: ZOVIRAX for Injection is indicated for the treatment of severe initial clinical episodes of herpes genitalis in immunocompetent patients.
Herpes Simplex Encephalitis: ZOVIRAX for Injection is indicated for the treatment of herpessimplex encephalitis.
Neonatal Herpes Simplex Virus Infection: ZOVIRAX for Injection is indicated for the treatmentof neonatal herpes infections.
Varicella-Zoster Infections in Immunocompromised Patients: ZOVIRAX for Injection is
indicated for the treatment of varicella-zoster (shingles) infections in immunocompromised patients. Launch Date3.86208006E11 |
|||
Primary | VALTREX Approved UseINDICATIONS AND USAGE. VALTREX is a nucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients Cold Sores (Herpes Labialis), Genital Herpes, Treatment in immunocompetent patients (initial or recurrent episode), Suppression in immunocompetent or HIV-infected patients, Reduction of transmission, Herpes Zoster. Pediatric Patients Cold Sores (Herpes Labialis), Chickenpox Limitations of Use. The efficacy and safety of VALTREX have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients. Launch Date1.07896321E12 |
|||
Primary | VALTREX Approved UseINDICATIONS AND USAGE. VALTREX is a nucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients Cold Sores (Herpes Labialis), Genital Herpes, Treatment in immunocompetent patients (initial or recurrent episode), Suppression in immunocompetent or HIV-infected patients, Reduction of transmission, Herpes Zoster. Pediatric Patients Cold Sores (Herpes Labialis), Chickenpox Limitations of Use. The efficacy and safety of VALTREX have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients. Launch Date1.07887683E12 |
|||
Primary | VALTRE Approved UseINDICATIONS AND USAGE. VALTREX is a nucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients Cold Sores (Herpes Labialis), Genital Herpes, Treatment in immunocompetent patients (initial or recurrent episode), Suppression in immunocompetent or HIV-infected patients, Reduction of transmission, Herpes Zoster. Pediatric Patients Cold Sores (Herpes Labialis), Chickenpox Limitations of Use. The efficacy and safety of VALTREX have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients. Launch Date1.07887683E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
599.2 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17692728 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACYCLOVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3015.7 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17692728 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACYCLOVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.9 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17692728 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACYCLOVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
79% |
ACYCLOVIR plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
weak | ||||
yes | ||||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
no | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Flow cytometric evaluation of antiviral agents against human herpesvirus 6. | 2001 |
|
Atypical Herpes simplex keratitis (HSK) presenting as a perforated corneal ulcer with a large infiltrate in a contact lens wearer: multinucleated giant cells in the Giemsa smear offered a clue to the diagnosis. | 2001 |
|
A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. | 2001 |
|
Prophylaxis against herpesvirus infections in transplant recipients. | 2001 |
|
Management of neonatal herpes simplex virus infection. | 2001 |
|
Recent advances in imaging endogenous or transferred gene expression utilizing radionuclide technologies in living subjects: applications to breast cancer. | 2001 |
|
Cough syncope with herpetic tracheobronchitis. | 2001 Apr |
|
Rotavirus encephalopathy: pathogenesis reviewed. | 2001 Apr |
|
Heart transplantation and the Batista operation for children with refractory heart failure. | 2001 Apr |
|
Treatment of EBV driven lymphoproliferation with erythrophagocytosis: 12 year follow up. | 2001 Apr |
|
Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. | 2001 Apr |
|
[Peptide transporter family]. | 2001 Apr |
|
Acyclovir treatment in 2 patients with benign trigeminal sensory neuropathy. | 2001 Apr |
|
Biological characterization of eugeniin as an anti-herpes simplex virus type 1 compound in vitro and in vivo. | 2001 Apr |
|
Practice parameter: Steroids, acyclovir, and surgery for Bell's palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. | 2001 Apr 10 |
|
Hydrophilic interaction chromatography using amino and silica columns for the determination of polar pharmaceuticals and impurities. | 2001 Apr 13 |
|
Painful skin erosions and fever in an infant. Eczema herpeticum. | 2001 Feb |
|
Prophylaxis of intravenous immunoglobulin and acyclovir in perinatal varicella. | 2001 Feb |
|
Pretransplant varicella vaccination is cost-effective in pediatric renal transplantation. | 2001 Feb |
|
Anti-herpesvirus activity of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)-cycloprop-1'-yl]methyl] x guanine (A-5021) in vitro and in vivo. | 2001 Feb |
|
Genetic risks of antiviral nucleoside analogues--a survey. | 2001 Feb |
|
Viral etiologies of encephalitis in Thai children. | 2001 Feb |
|
Meta-analysis of prophylaxis of CMV disease in solid organ transplantation: is Ganciclovir a superior agent to Acyclovir? | 2001 Feb-Mar |
|
Prophylactic antiviral therapy in CMV high-risk liver transplant recipients. | 2001 Feb-Mar |
|
Antiviral drugs can inhibit lymphocyte apoptosis induced by cytomegalovirus antigens. | 2001 Feb-Mar |
|
Recurrent herpes labialis: efficacy of topical therapy with penciclovir compared with acyclovir (aciclovir). | 2001 Jan |
|
Topical treatment of recurrent herpes labialis. | 2001 Jan |
|
Aerobic bacterial and fungal infections in peripheral blood stem cell transplants. | 2001 Jan |
|
[Valaciclovir in the treatment of initial infection by genital herpes virus: comparative study]. | 2001 Jan |
|
Epstein-Barr virus-related lymphoproliferative disease complicating childhood acute lymphoblastic leukemia: no recurrence after unrelated donor bone marrow transplantation. | 2001 Jan |
|
Novel synthesis of seco type of acyclo C-nucleosides of 1,2,4-triazole and 1,2,4-triazol. | 2001 Jan-Feb |
|
Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy)butyl]guanine. | 2001 Jun |
|
Mild herpes simplex encephalitis worsening despite acyclovir treatment. | 2001 Mar |
|
[Highly active antiviral and immunosuppressive combination therapy with acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease]. | 2001 Mar |
|
[Benign acute ataxia in an adult with VZV infection]. | 2001 Mar |
|
A pilot study of treatment of herpes labialis with 1072 nm narrow waveband light. | 2001 Mar |
|
[Neurologic toxicity caused by zelitrex (valaciclovir) in 3 patients with renal failure. Is overdose associated with improvement of product bioavailability improvement?]. | 2001 Mar |
|
A 35-year-old man with recurrent aseptic meningitis. | 2001 Mar |
|
Predictors of recurrent herpes simplex virus keratitis. Herpetic Eye Disease Study Group. | 2001 Mar |
|
Investigation of aciclovir-resistant herpes simplex virus I infection in a bone marrow transplantation unit: genotyping shows that different strains are involved. | 2001 Mar |
|
Long-term high-dose acyclovir and AIDS-related non-Hodgkins lymphoma. | 2001 Mar 15 |
|
The management of varicella-zoster virus exposure and infection in pregnancy and the newborn period. Australasian Subgroup in Paediatric Infectious Diseases of the Australasian Society for Infectious Diseases. | 2001 Mar 19 |
|
Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study. | 2001 Mar-Apr |
|
[Intrauterine herpes simplex virus infection]. | 2001 Mar-Apr |
|
Coexpression of guanylate kinase with thymidine kinase enhances prodrug cell killing in vitro and suppresses vascular smooth muscle cell proliferation in vivo. | 2001 May |
|
Oral recurrent human herpes virus infection and bone marrow transplantation survival. | 2001 May |
|
Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study. | 2001 May |
|
Contact dermatitis from topical antiviral drugs. | 2001 May |
|
Enhancement of the anti-herpetic effect of trichosanthin by acyclovir and interferon. | 2001 May 11 |
|
Synthesis and biological evaluation of purine-containing butenolides. | 2001 May 24 |
Sample Use Guides
Acute Treatment of Herpes Zoster: 800 mg every 4 hours orally, 5 times daily for 7 to 10 days.
Genital Herpes: Treatment of Initial Genital Herpes: 200 mg every 4 hours, 5 times daily for
10 days.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1329640
Penciclovir (PCV) and acyclovir are acyclic guanine analogs which inhibit herpes simplex virus (HSV) DNA polymerase. Their 50% infective doses were 0.5 to 0.8 microgram/ml for clinical isolates of HSV-1 and 1.3 to 2.2 micrograms/ml for HSV-2.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 16:58:42 UTC 2022
by
admin
on
Fri Dec 16 16:58:42 UTC 2022
|
Record UNII |
X4HES1O11F
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C281
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
NDF-RT |
N0000175468
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
NDF-RT |
N0000175459
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
WHO-VATC |
QS01AD03
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
FDA ORPHAN DRUG |
313210
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
21.1
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
FDA ORPHAN DRUG |
513615
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.1
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
WHO-VATC |
QD06BB53
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
NDF-RT |
N0000175459
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
NDF-RT |
N0000180187
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
WHO-ATC |
D06BB03
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
WHO-ATC |
D06BB53
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
NCI_THESAURUS |
C1556
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
WHO-ATC |
J05AB01
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
WHO-VATC |
QD06BB03
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
WHO-VATC |
QJ05AB01
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
FDA ORPHAN DRUG |
325010
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
WHO-ATC |
S01AD03
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
NDF-RT |
N0000020060
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
LIVERTOX |
NBK548548
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
NDF-RT |
N0000180188
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
NCI_THESAURUS |
C29575
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
FDA ORPHAN DRUG |
37589
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
||
|
NDF-RT |
N0000175459
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1012065
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | |||
|
4829
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | |||
|
DTXSID1022556
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | |||
|
59277-89-3
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | |||
|
758477
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | |||
|
85
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | |||
|
DB00787
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | |||
|
645011
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | |||
|
6511
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | |||
|
X4HES1O11F
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | |||
|
ACICLOVIR
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | |||
|
2453
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | |||
|
CHEMBL184
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | |||
|
Acyclovir
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | |||
|
D000212
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | |||
|
C205
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | |||
|
X4HES1O11F
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | |||
|
4435
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | |||
|
261-685-1
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | |||
|
M1404
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | Merck Index | ||
|
ACYCLOVIR
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | Description: White or almost white, crystalline powder. Solubility: Slightly soluble in water; freely soluble in dimethyl sulfoxide; very slightly soluble in ethanol (96%). It dissolves in dilute solutions of mineral acids and alkali hydroxides. Category: Antiviral (Purine nucleoside analogue). Storage: Preserve in well-closed containers. Protect from light and moisture. Additional information: Aciclovir may exhibit polymorphism. Definition: Aciclovir contains not less than 98.5% and not more than 101.0% of C8H11N5O3, calculated with reference to the dried substance. | ||
|
281
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | RxNorm | ||
|
135398513
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY | |||
|
SUB05235MIG
Created by
admin on Fri Dec 16 16:58:42 UTC 2022 , Edited by admin on Fri Dec 16 16:58:42 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE |
Km
|
||
|
BINDER->LIGAND |
acyclovir crosses the placenta
BINDING
|
||
|
TRANSPORTER -> SUBSTRATE |
Km
|
||
|
EXCRETED UNCHANGED |
URINE
|
||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
TRANSPORTER -> SUBSTRATE |
Vmax
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> SUBSTRATE |
Vmax
|
||
|
ACTIVE CONSTITUENT ALWAYS PRESENT -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TRANSPORTER -> SUBSTRATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
|
||
|
IMPURITY -> PARENT |
sum of impurities K and R: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.15 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
sum of impurities A and B: maximum 2.0 per cent; for the calculation of content, multiply the peak area of impurities A and B by 0.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
sum of impurities A and B: maximum 2.0 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
|
||
|
IMPURITY -> PARENT |
IDENTIFIED AS IMPURITY K
The following peaks are eluted at the following relative retention with reference to the peak of aciclovir (retention time about 13 min): impurity K about 2.5.
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
ACYCLOVIR IMPURITY L AMOUNT NOT SPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities K and R: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.15 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Cmax | PHARMACOKINETIC |
|
ROUTE OF ADMINSTRATION PHARMACOKINETIC PHARMACOKINETIC |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
|
|||
CSF/PLASMA RATIO | PHARMACOKINETIC |
|
||||
Biological Half-life | PHARMACOKINETIC |
|
|
|||